A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin-Reference-Cited by-同舟云学术

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin

Published:2022-04-18 Issue:4 Volume:40 Page:782-788
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

McLean Luke S,Morris Tessa A,Gramza Ann,Liu Stephen,Khan Saad A.,Colevas A. Dimitrios,Pearce Tillman,Rischin Danny

Funder

Threshold Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-022-01230-w.pdf

Reference29 articles.

1. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928. https://doi.org/10.1016/s0140-6736(19)32591-7

2. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD et al (2018) PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379(4):341–351. https://doi.org/10.1056/nejmoa1805131

3. Thariat J, Milas L, Ang KK (2007) Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69(4):974–984. https://dx.doi.org/10.1016%2Fj.ijrobp.2007.06.076

4. Nordsmark M, Overgaard J (2004) Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 43(4):396–403. https://doi.org/10.1080/02841860410026189

5. Rischin D, Fisher R, Peters L, Corry J, Hicks R (2007) Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys 69(2 Suppl): S61–S63 https://doi.org/10.1016/j.ijrobp.2007.05.043

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer;Archives of Toxicology;2024-01-11

4. AGENTES ANTINEOPLÁSICOS BIORREDUTÍVEIS: AVANÇOS E DESAFIOS APÓS 20 ANOS;Química Nova;2024

5. The Biocatalysis in Cancer Therapy;ACS Catalysis;2023-05-25